Umbhali: William Ramirez
Umhla Wokudalwa: 16 Eyomsintsi 2021
Hlaziya Umhla: 21 Isilimela 2024
Anonim
What Doctors are saying about CBD? | Cannabidiol
Ividiyo: What Doctors are saying about CBD? | Cannabidiol

Umxholo

I-Cannabidiol yikhemikhali kwisityalo se-Cannabis sativa, esaziwa ngokuba yi-marijuana okanye i-hemp. Ngaphezulu kweekhemikhali ezingama-80, ezaziwa ngokuba zii-cannabinoids, zichongiwe kwisityalo seCannabis sativa. Ngelixa i-delta-9-tetrahydrocannabinol (THC) sesona sithako siphambili sentsangu, i-cannabidiol ikwafumaneka kwi-hemp, enexabiso elincinci kakhulu le-THC.

Ukuwiswa kweBhili yeFama ye-2018 kuyenze ngokusemthethweni ukuthengisa iihempe kunye neemveliso ze-hemp e-U.S. Kodwa oko akuthethi ukuba zonke iimveliso ze-hemp-derived cannabidiol zisemthethweni. Kuba i-cannabidiol ifundwe njengechiza elitsha, ayinakubandakanywa ngokusemthethweni kukutya okanye kwizongezo zokutya. Kwakhona, i-cannabidiol ayinakufakwa kwiimveliso ezithengiswa ngamabango onyango. I-Cannabidiol inokufakwa kuphela kwiimveliso "zokuthambisa" kwaye kuphela ukuba iqulethe ngaphantsi kwe-0.3% THC. Kodwa kusekho iimveliso ezibhalwe njengezongezo zokutya kwimarike equlathe i-cannabidiol. Inani le-cannabidiol equlethwe kwezi mveliso alisoloko lichazwa ngokuchanekileyo kwileyibhile yemveliso.

I-Cannabidiol ixhaphake kakhulu kwisifo sokuxhuzula (isifo sokuwa). Isetyenziselwa uxinzelelo, iintlungu, ukuphazamiseka kwemisipha okubizwa ngokuba yi-dystonia, isifo sika-Parkinson, isifo se-Crohn, kunye nezinye iimeko ezininzi, kodwa abukho ubungqina benzululwazi obuxhasa ezi zinto zisetyenziswayo.

Amayeza endalo aVimba weDatha Ukusebenza kwexabiso ngokusekwe kubungqina besayensi ngokwala manqanaba alandelayo: Ukusebenza, ukusebenza ngokukuko, okunokwenzeka ukuba kusebenze, okungenzeka kungasebenzi, kunokwenzeka ukungasebenzi, ukungasebenzi, kunye nobungqina obungonelanga bokulinganisa.

Ukulinganiswa kokusebenza kwe ICANABIDIOL (CBD) zezi zilandelayo:


Kusenokwenzeka ukuba iyasebenza ...

  • Ukuphazamiseka kwengqondo (isifo sokuwa). Imveliso ethile ye-cannabidiol (Epidiolex, GW Pharmaceuticals) ibonakalisiwe ukunciphisa ukubanjwa kwabantu abadala kunye nabantwana abaneemeko ezahlukeneyo ezinxulunyaniswa nokubanjwa. Le mveliso sisiyobisi esinyangiweyo sokunyanga ukuxhuzula okubangelwa yi-Dravet syndrome, i-Lennox-Gastaut syndrome, okanye i-tuberous sclerosis complex. Kukwabonakalisiwe ukunciphisa ukubanjwa kwabantu abane-Sturge-Weber syndrome, isifo esosuleleko esimalunga nesifo sokuwa (i-FIRES), kunye nokuphazamiseka okuthile kwemfuza okubangela ukunganyaniseki. Kodwa ayivunyelwanga ukunyanga ezinye iintlobo zokubanjwa. Le mveliso ihlala ithathwa ngokudibanisa namayeza aqhelekileyo okulwa nokuhlutha. Ezinye iimveliso ze-cannabidiol ezenziwe elebhu ziyafundwa nokuxhuzula. Kodwa uphando lilinganiselwe, kwaye akukho nanye kwezi mveliso evunyiweyo njengamayeza kagqirha.

Akukho bungqina baneleyo bokulinganisa ukusebenza ...

  • Uhlobo lwesifo sokukrala kwamathumbu (isifo seCrohn). Uphando lwakwangoko lubonisa ukuba ukuthatha i-cannabidiol akuyinciphisi imisebenzi yesifo kubantu abadala abanesifo seCrohn.
  • Seswekile. Uphando lwakwangoko lubonisa ukuba ukuthatha i-cannabidiol akukuphuculi ukulawulwa kweglucose yabantu abadala abane-2 yeswekile.
  • Ingxaki yokuhamba ephawulwe ngokungahambelani kwemisipha (dystonia). Akucaci ukuba i-cannabidiol iluncedo kwi-dystonia.
  • Imeko ezuzwe njengelifa ephawulwe kukukhubazeka ekufundeni (ethe-X syndrome). Uphando lwakwangoko lubonisa ukuba ukusebenzisa ijeli ye-cannabidiol kunokunciphisa uxinzelelo kunye nokuphucula indlela yokuziphatha kubantwana abane-X syndrome.
  • Imeko apho ukufakelwa komzimba kuhlasela umzimba (isifo se-graft-versus-host host okanye i-GVHD). Isifo se-Graft-versus-host is a complication that can occur after a bone marrow transplant. Uphando lwakwangoko lufumanise ukuba ukuthatha i-cannabidiol yonke imihla ukuqala kwiintsuku ezisi-7 ngaphambi kokufakelwa komongo wethambo kunye nokuqhubeka kangangeentsuku ezingama-30 emva kokufakelwa kunokonyusa ixesha elithathwayo ukuze umntu avelise i-GVHD.
  • Ukuphazamiseka kwengqondo okuzuze ilifa okuchaphazela iintshukumo, iimvakalelo kunye nokucinga (Isifo sikaHuntington). Uphando lwakwangoko lubonisa ukuba ukuthatha i-cannabidiol yonke imihla akuphuculi zimpawu zesifo sikaHuntington.
  • Multiple sclerosis (MS). Uphando lwakwangoko lubonisa ukuba ukusebenzisa isitshizi se-cannabidiol phantsi kolwimi kunokuphucula iintlungu kunye nokuqina kwemisipha kubantu abane-MS.
  • Ukurhoxa kwi-heroin, morphine, kunye nezinye iziyobisi ze-opioid. Uphando lwakwangoko lubonisa ukuba ukuthatha i-cannabidiol kangangeentsuku ezi-3 kunokunciphisa iminqweno kunye noxinzelelo kubantu abanengxaki yokusebenzisa i-heroin.
  • Isifo seParkinson. Uphando lwakwangoko lubonisa ukuba i-cannabidiol inokunciphisa uxinzelelo kunye neempawu zengqondo kubantu abanesifo sikaParkinson.
  • Ischizophrenia. Uphando lwakwangoko lubonisa ukuba ukuthatha i-cannabidiol kuphucula iimpawu kunye nokuba sempilweni kwabantu abane-schizophrenia.
  • Ukuyeka ukutshaya. Uphando lwakwangoko lubonisa ukuba ukusezela i-cannabidiol nge-inhaler kwiveki enye kunokunciphisa inani lecuba elitshaywa ngabantu abatshayayo abazama ukuyeka.
  • Uhlobo loxinzelelo oluphawulwe luloyiko kwezinye okanye kuzo zonke iisetingi zentlalo (ingxaki yoxinzelelo lwentlalo). Uphando lwakwangoko lubonisa ukuba i-cannabidiol inokuphucula uxinzelelo kubantu abanale ngxaki. Kodwa akucaci ukuba kuyanceda ukunciphisa uxinzelelo ngexesha lokuthetha esidlangalaleni.
  • Iqela leemeko ezibuhlungu ezichaphazela ukudibana kwemihlathi kunye nezihlunu (iingxaki zetemporomandibular okanye i-TMD). Uphando lwakwangoko lubonisa ukuba ukusebenzisa ioyile equlethe i-cannabidiol kulusu kunokunciphisa iintlungu kubantu abane-TMD.
  • Umonakalo wemithambo ezandleni nasezinyaweni (peripheral neuropathy).
  • Ukuxhuzula.
  • Ukuphuthelwa.
  • Ezinye iimeko.
Ubungqina obungakumbi buyafuneka ukukala ukusebenza kwe-cannabidiol kwezi zinto zisetyenziswayo.

I-Cannabidiol ineziphumo kwingqondo. Oyena nobangela wale miphumela akucaci. Nangona kunjalo, i-cannabidiol ibonakala ikuthintela ukonakala kwemichiza kwingqondo echaphazela iintlungu, imo yokusebenza kunye nokusebenza kwengqondo. Ukuthintela ukonakala kwale khemikhali kunye nokwandisa amanqanaba ayo egazini kubonakala kunciphisa iimpawu zengqondo ezinxulumene neemeko ezinje ngesifo sengqondo. I-Cannabidiol inokuthintela ezinye zeempembelelo zengqondo ze-delta-9-tetrahydrocannabinol (THC). Kwakhona, i-cannabidiol ibonakala inciphisa iintlungu noxinzelelo.

Xa kuthathwa ngomlomo: ICannabidiol yiyo UKHUSELEKO OLUNOKWENZEKA xa ithathwa ngomlomo okanye itshizwe phantsi kolwimi ngokufanelekileyo. I-Cannabidiol ngeedosi ukuya kuthi ga kwi-300 mg yonke imihla ithathwe ngomlomo ngokukhuselekileyo ukuya kuthi ga kwiinyanga ezi-6. Amayeza aphezulu e-1200-1500 mg yonke imihla athathwe ngomlomo ngokukhuselekileyo ukuya kuthi ga kwiiveki ezi-4. Imveliso ye-cannabidiol yemithi (i-Epidiolex) ivunyiwe ukuba ithathwe ngomlomo ngeedosi ukuya kuthi ga kwi-25 mg / kg yonke imihla. Izitshizi zeCannabidiol ezisetyenziswa phantsi kolwimi zisetyenziswe kumthamo we-2.5 mg ukuya kuthi ga kwiiveki ezi-2.

Ezinye iziphumo ezichaziweyo ze-cannabidiol zibandakanya umlomo owomileyo, uxinzelelo lwegazi oluphantsi, ukukhanya okukhanyayo kunye nokozela. Iimpawu zokulimala kwesibindi ziye zaxelwa kwezinye izigulana, kodwa oku akuqhelekanga.

Xa isetyenziswa eluswini: Akukho lwazi lwaneleyo oluthembekileyo lokwazi ukuba i-cannabidiol ikhuselekile okanye nokuba ziziphi na iziphumo ebezingalindelekanga ezinokuba khona.

Amanyathelo okhuseleko kunye nezilumkiso:

Ukukhulelwa kunye nokuncancisa: ICannabidiol yiyo OKUNGENZEKA UKHUSELEKILE ukusebenzisa xa ukhulelwe okanye uncancisa. Iimveliso zeCannabidiol zinokungcoliseka zezinye izinto ezinokuba yingozi kwimveku okanye usana. Hlala kwicala elikhuselekileyo kwaye uphephe ukusetyenziswa.

AbantwanaImveliso kagqirha ye-cannabidiol (Epidiolex) yile UKHUSELEKO OLUNOKWENZEKA xa uthathwa ngomlomo ngeedosi ukuya kuthi ga kwi-25 mg / kg yonke imihla. Le mveliso ivunyiwe ukuba isetyenziswe kubantwana abathile abaneminyaka eli-1 ubudala nangaphezulu.

Isifo sesibindiAbantu abanesifo sesibindi banokufuna ukusebenzisa iidosi ezisezantsi ze-cannabidiol xa kuthelekiswa nezigulana ezisempilweni.

Isifo seParkinson: Olunye uphando lwakwangoko lubonisa ukuba ukuthatha iidosi eziphezulu ze-cannabidiol kunokwenza intshukumo yemisipha kunye neenyikima zibe mbi ngakumbi kwabanye abantu abanesifo seParkinson.

Iphakathi
Lumka ngale nhlanganisela.
IBrivaracetam (Briviact)
I-Brivaracetam iyatshintshwa kwaye yaphulwe ngumzimba. I-Cannabidiol inokunciphisa ngokukhawuleza ukuba umzimba uphule njani i-brivaracetam. Oku kunokunyusa amanqanaba e-brivaracetam emzimbeni.
ICarbamazepine (iTegretol)
ICarbamazepine iyatshintshwa kwaye yaphulwe ngumzimba. I-Cannabidiol inokunciphisa ngokukhawuleza ukuba umzimba uphule njani i-carbamazepine. Oku kunokunyusa amanqanaba e-carbamazepine emzimbeni kunye nokunyusa iziphumo ebezingalindelekanga.
IClobazam (Onfi)
I-Clobazam iyatshintshwa kwaye yaphulwe sisibindi. I-Cannabidiol inokunciphisa ngokukhawuleza ukuba isibindi sichitha i-clobazam. Oku kunokunyusa iziphumo kunye neziphumo ebezingalindelekanga ze-clobazam.
I-Eslicarbazepine (iAptiom)
I-Eslicarbazepine iyatshintshwa kwaye yaphulwe ngumzimba. I-Cannabidiol inokunciphisa ngokukhawuleza ukuba umzimba uphula njani i-eslicarbazepine. Oku kunokunyusa amanqanaba e-eslicarbazepine emzimbeni ngenani elincinci.
Everolimus (iZostress)
I-Everolimus iyatshintshwa kwaye yaphulwe ngumzimba. I-Cannabidiol inokunciphisa ngokukhawuleza ukuba umzimba uphule njani i-everolimus. Oku kunokunyusa amanqanaba e-everolimus emzimbeni.
ILithium
Ukuthatha iidosi eziphezulu ze-cannabidiol kunokunyusa amanqanaba e-lithium. Oku kunokunyusa umngcipheko we-lithium toxicity.
Amayeza atshintshwe sisibindi (iiCytochrome P450 1A1 (CYP1A1) substrates)
Amanye amayeza atshintshiwe kwaye aphulwe sisibindi. I-Cannabidiol inokunciphisa ngokukhawuleza ukuba isibindi siphula amayeza athile. Kwithiyori, ukusebenzisa i-cannabidiol kunye namanye amayeza aphulwe sisibindi kunokunyusa iziphumo kunye neziphumo ebezingalindelekanga zamayeza athile. Ngaphambi kokusebenzisa i-cannabidiol, thetha nomboneleli wakho wezempilo ukuba uthatha nawaphi na amayeza atshintshwa sisibindi.

Amanye amayeza atshintshwe sisibindi kubandakanya i-chlorzoxazone (i-Lorzone) kunye ne-theophylline (Theo-Dur, abanye).
Amayeza atshintshwe sisibindi (iiCytochrome P450 1A2 (CYP1A2) substrates)
Amanye amayeza atshintshiwe kwaye aphulwe sisibindi. I-Cannabidiol inokunciphisa ngokukhawuleza ukuba isibindi siphula amayeza athile. Kwithiyori, ukusebenzisa i-cannabidiol kunye namanye amayeza aphulwe sisibindi kunokunyusa iziphumo kunye neziphumo ebezingalindelekanga zamayeza athile. Ngaphambi kokusebenzisa i-cannabidiol, thetha nomboneleli wakho wezempilo ukuba uthatha nawaphi na amayeza atshintshwa sisibindi.

Amanye amayeza atshintshwe sisibindi kubandakanya amitriptyline (Elavil), haloperidol (Haldol), ondansetron (Zofran), propranolol (Inderal), theophylline (Theo-Dur, abanye), verapamil (Calan, Isoptin, abanye), kunye nabanye.
Amayeza atshintshwe sisibindi (iiCytochrome P450 1B1 (CYP1B1) substrates)
Amanye amayeza atshintshiwe kwaye aphulwe sisibindi. I-Cannabidiol inokunciphisa ngokukhawuleza ukuba isibindi siphula amayeza athile. Kwithiyori, ukusebenzisa i-cannabidiol kunye namanye amayeza aphulwe sisibindi kunokunyusa iziphumo kunye neziphumo ebezingalindelekanga zamayeza athile. Ngaphambi kokusebenzisa i-cannabidiol, thetha nomboneleli wakho wezempilo ukuba uthatha nawaphi na amayeza atshintshwa sisibindi.

Amanye amayeza atshintshwe sisibindi abandakanya i-theophylline (Theo-Dur, abanye), omeprazole (Prilosec, Omesec), clozapine (Clozaril, FazaClo), progesterone (Prometrium, abanye), lansoprazole (Prevacid), flutamide (Eulexin), oxaliplatin (Eloxatin ), erlotinib (Tarceva), kunye necaffeine.
Amayeza atshintshwe sisibindi (iiCytochrome P450 2A6 (CYP2A6) substrates)
Amanye amayeza atshintshiwe kwaye aphulwe sisibindi. I-Cannabidiol inokunciphisa ngokukhawuleza ukuba isibindi siphula amayeza athile. Kwithiyori, ukusebenzisa i-cannabidiol kunye namanye amayeza aphulwe sisibindi kunokunyusa iziphumo kunye neziphumo ebezingalindelekanga zamayeza athile. Ngaphambi kokusebenzisa i-cannabidiol, thetha nomboneleli wakho wezempilo ukuba uthatha nawaphi na amayeza atshintshwa sisibindi.

Amanye amayeza atshintshwe sisibindi aquka inicotine, chlormethiazole (Heminevrin), coumarin, methoxyflurane (Penthrox), halothane (Fluothane), valproic acid (Depacon), disulfiram (Antabuse), kunye nezinye.
Amayeza atshintshwe sisibindi (iiCytochrome P450 2B6 (CYP2B6) substrates)
Amanye amayeza atshintshiwe kwaye aphulwe sisibindi. I-Cannabidiol inokunciphisa ngokukhawuleza ukuba isibindi siphula amayeza athile. Kwithiyori, ukusebenzisa i-cannabidiol kunye namanye amayeza aphulwe sisibindi kunokunyusa iziphumo kunye neziphumo ebezingalindelekanga zamayeza athile. Ngaphambi kokusebenzisa i-cannabidiol, thetha nomboneleli wakho wezempilo ukuba uthatha nawaphi na amayeza atshintshwa sisibindi.

Amanye amayeza atshintshwe sisibindi aquka i-ketamine (Ketalar), phenobarbital, orphenadrine (Norflex), secobarbital (Seconal), kunye ne-dexamethasone (Decadron).
Amayeza atshintshwe sisibindi (iiCytochrome P450 2C19 (CYP2C19) substrates)
Amanye amayeza atshintshiwe kwaye aphulwe sisibindi. I-Cannabidiol inokunciphisa ngokukhawuleza ukuba isibindi siphula amayeza athile. Kwithiyori, ukusebenzisa i-cannabidiol kunye namanye amayeza aphulwe sisibindi kunokunyusa iziphumo kunye neziphumo ebezingalindelekanga zamayeza athile. Ngaphambi kokusebenzisa i-cannabidiol, thetha nomboneleli wakho wezempilo ukuba uthatha nawaphi na amayeza atshintshwa sisibindi.

Amanye amayeza atshintshwe sisibindi kubandakanya iproton pump inhibitors kubandakanya i-omeprazole (Prilosec), i-lansoprazole (Prevacid), kunye ne-pantoprazole (Protonix); diazepam (Valium); icarisoprodol (iSoma); i-nelfinavir (iViracept); nabanye.
Amayeza atshintshwe sisibindi (iiCytochrome P450 2C8 (CYP2C8) substrates)
Amanye amayeza atshintshiwe kwaye aphulwe sisibindi. I-Cannabidiol inokunciphisa ngokukhawuleza ukuba isibindi siphula amayeza athile. Kwithiyori, ukusebenzisa i-cannabidiol kunye namanye amayeza aphulwe sisibindi kunokunyusa iziphumo kunye neziphumo ebezingalindelekanga zamayeza athile. Ngaphambi kokusebenzisa i-cannabidiol, thetha nomboneleli wakho wezempilo ukuba uthatha nawaphi na amayeza atshintshwa sisibindi.
Amanye amayeza atshintshwe sisibindi aquka i-amiodarone (Cordarone), i-carbamazepine (Tegretol), i-chloroquine (Aralen), i-diclofenac (i-Voltaren), i-paclitaxel (i-Taxol), i-repaglinide (i-Prandin) kunye nezinye.
Amayeza atshintshwe sisibindi (iiCytochrome P450 2C9 (CYP2C9) substrates)
Amanye amayeza atshintshiwe kwaye aphulwe sisibindi. I-Cannabidiol inokunciphisa ngokukhawuleza ukuba isibindi siphula amayeza athile. Kwithiyori, ukusebenzisa i-cannabidiol kunye namanye amayeza aphulwe sisibindi kunokunyusa iziphumo kunye neziphumo ebezingalindelekanga zamayeza athile. Ngaphambi kokusebenzisa i-cannabidiol, thetha nomboneleli wakho wezempilo ukuba uthatha nawaphi na amayeza atshintshwa sisibindi.

Amanye amayeza atshintshwe sisibindi kubandakanya iziyobisi ezingezizo ezokulwa nokudumba (i-NSAID) ezinje nge-diclofenac (Cataflam, Voltaren), ibuprofen (Motrin), meloxicam (Mobic), piroxicam (Feldene), kunye ne-celecoxib (Celebrex); umgca we-amitriptyline (Elavil); iwarfarin (Coumadin); glipizide (Glucotrol); losartan (uCozaar); nabanye.
Amayeza atshintshwe sisibindi (iiCytochrome P450 2D6 (CYP2D6) substrates)
Amanye amayeza atshintshiwe kwaye aphulwe sisibindi. I-Cannabidiol inokunciphisa ngokukhawuleza ukuba isibindi siphula amayeza athile. Kwithiyori, ukusebenzisa i-cannabidiol kunye namanye amayeza aphulwe sisibindi kunokunyusa iziphumo kunye neziphumo ebezingalindelekanga zamayeza athile. Ngaphambi kokusebenzisa i-cannabidiol, thetha nomboneleli wakho wezempilo ukuba uthatha nawaphi na amayeza atshintshwa sisibindi.

Amanye amayeza atshintshwe sisibindi kubandakanya amitriptyline (Elavil), codeine, desipramine (Norpramin), flecainide (Tambocor), haloperidol (Haldol), imipramine (Tofranil), metoprolol (Lopressor, Toprol XL), ondansetron (Zofran), paroxetine (Paxiletine) ), risperidone (Risperdal), tramadol (Ultram), venlafaxine (Effexor), kunye nezinye.
Amayeza atshintshwe sisibindi (iiCytochrome P450 3A4 (CYP3A4) substrates)
Amanye amayeza atshintshiwe kwaye aphulwe sisibindi. I-Cannabidiol inokunciphisa ngokukhawuleza ukuba isibindi siphula amayeza athile. Kwithiyori, ukusebenzisa i-cannabidiol kunye namanye amayeza aphulwe sisibindi kunokunyusa iziphumo kunye neziphumo ebezingalindelekanga zamayeza athile. Ngaphambi kokusebenzisa i-cannabidiol, thetha nomboneleli wakho wezempilo ukuba uthatha nawaphi na amayeza atshintshwa sisibindi.

Amanye amayeza atshintshwe sisibindi aquka i-alprazolam (Xanax), i-amlodipine (i-Norvasc), i-clarithromycin (i-Biaxin), i-cyclosporine (iSandimmune), i-erythromycin, i-lovastatin (i-Mevacor), i-ketoconazole (i-Nizoral), i-itraconazole (i-Sporanox), i-fexofenadine (Halcion), verapamil (Calan, Isoptin) kunye nabanye abaninzi.
Amayeza atshintshwe sisibindi (iiCytochrome P450 3A5 (CYP3A5) substrates)
Amanye amayeza atshintshiwe kwaye aphulwe sisibindi. I-Cannabidiol inokunciphisa ngokukhawuleza ukuba isibindi siphula amayeza athile. Kwithiyori, ukusebenzisa i-cannabidiol kunye namanye amayeza aphulwe sisibindi kunokunyusa iziphumo kunye neziphumo ebezingalindelekanga zamayeza athile. Ngaphambi kokusebenzisa i-cannabidiol, thetha nomboneleli wakho wezempilo ukuba uthatha nawaphi na amayeza atshintshwa sisibindi.

Amanye amayeza atshintshwe sisibindi kubandakanya testosterone, progesterone (Endometrin, Prometrium), nifedipine (Adalat CC, Procardia XL), cyclosporine (Sandimmune), kunye nezinye.
Amachiza atshintshwe sisibindi (iziyobisi ezinesibindi)
Amanye amayeza atshintshiwe kwaye aphulwe sisibindi. I-Cannabidiol inokunciphisa ngokukhawuleza ukuba isibindi siphula amayeza athile. Ukuthatha i-cannabidiol kunye namanye amayeza aphulwe sisibindi kunokunyusa iziphumo kunye neziphumo zala mayeza.
Amanye ala mayeza atshintshwe sisibindi kubandakanya i-acetaminophen (iTylenol, abanye) kunye ne-oxazepam (Serax), haloperidol (Haldol), lamotrigine (Lamictal), morphine (MS Contin, Roxanol), zidovudine (AZT, Retrovir), kunye nezinye.
Amayeza anciphisa ukwehla kwamanye amayeza sisibindi (I-Cytochrome P450 2C19 (CYP2C19) inhibitors)
I-Cannabidiol idilizwe sisibindi. Amanye amayeza anokunciphisa ngokukhawuleza ukuba isibindi sichitha i-cannabidiol ngokukhawuleza. Ukuthatha i-cannabidiol kunye nala mayeza kunokunyusa iziphumo kunye neziphumo ze-cannabidiol.
Amanye amayeza anokunciphisa ukophuka kwe-cannabidiol esibindini kubandakanya i-cimetidine (Tagamet), i-fluvoxamine (i-Luvox), i-omeprazole (Prilosec); ticlopidine (Ticlid), topiramate (Topamax), kunye nabanye.
Amayeza anciphisa ukwehla kwamanye amayeza esibindini (i-Cytochrome P450 3A4 (CYP3A4) inhibitors)
I-Cannabidiol idilizwe sisibindi. Amanye amayeza anokunciphisa ngokukhawuleza ukuba isibindi sichitha i-cannabidiol ngokukhawuleza. Ukuthatha i-cannabidiol kunye nala mayeza kunokunyusa iziphumo kunye neziphumo ze-cannabidiol.
Amanye amayeza anokunciphisa ngokukhawuleza ukuba isibindi siqhekeze i-cannabidiol kubandakanya i-amiodarone (Cordarone), i-clarithromycin (i-Biaxin), i-diltiazem (i-Cardizem), i-erythromycin (i-E-mycin, i-Erythrocin), i-indinavir (i-Crixivan), i-ritonavir (i-Norvir), i-saquinavir (i-Fortovase) , Invirase), kunye nabanye abaninzi.
Amachiza anyusa ukonakala kwamanye amayeza sisibindi (I-cytochrome P450 3A4 (CYP3A4) inducers)
I-Cannabidiol idilizwe sisibindi. Amanye amayeza anokunyusa ukuba isibindi siwaphule njani ngokukhawuleza i-cannabidiol. Ukuthatha i-cannabidiol kunye nala mayeza kunokunciphisa iziphumo ze-cannabidiol.
Amanye ala mayeza aquka i-carbamazepine (Tegretol), phenobarbital, phenytoin (Dilantin), rifampin, rifabutin (Mycobutin), kunye namanye.
Amachiza anyusa ukwaphuka kwamanye amayeza sisibindi (ICytochrome P450 2C19 (CYP2C19) inducers)
I-Cannabidiol idilizwe sisibindi. Amanye amayeza anokunyusa ukuba isibindi siwaphule njani ngokukhawuleza i-cannabidiol. Ukuthatha i-cannabidiol kunye nala mayeza kunokunciphisa iziphumo ze-cannabidiol.
Amanye amayeza anokunyusa ukonakala kwe-cannabidiol esibindini kubandakanya i-carbamazepine (Tegretol), i-prednisone (Deltasone), kunye ne-rifampin (i-Rifadin, i-Rimactane).
Imethadone (iDolophine)
IMethadone yophukile sisibindi. I-Cannabidiol inokunciphisa ngokukhawuleza ukuba isibindi sichitha i-methadone ngokukhawuleza. Ukuthatha i-cannabidiol kunye ne-methadone kunokunyusa iziphumo kunye neziphumo ebezingalindelekanga ze-methadone.
IRufinamide (iBanzel)
IRufinamide iyatshintshwa kwaye yaphulwe ngumzimba. I-Cannabidiol inokunciphisa ngokukhawuleza ukuba umzimba uphule njani i-rufinamide. Oku kunokunyusa amanqanaba e-rufinamide emzimbeni ngenani elincinci.
Amayeza okudambisa (i-CNS depressants)
I-Cannabidiol inokubangela ukozela nokozela. Amayeza abangela ubuthongo abizwa ngokuba kukuthomalalisa. Ukuthatha i-cannabidiol kunye namayeza okuthambisa kunokubangela ukulala kakhulu.

Amanye amayeza okuthambisa abandakanya i-benzodiazepines, ipentobarbital (Nembutal), phenobarbital (Luminal), secobarbital (Seconal), thiopental (Pentothal), fentanyl (Duragesic, Sublimaze), morphine, propofol (Diprivan), kunye nezinye.
Sirolimus (Rapamune)
I-Sirolimus iyatshintshwa kwaye yaphulwe ngumzimba. I-Cannabidiol inokunciphisa ngokukhawuleza ukuba umzimba uphule i-sirolimus. Oku kunokunyusa amanqanaba e-sirolimus emzimbeni.
I-Stiripentol (iDiacomit)
I-Stiripentol iyatshintshwa kwaye yaphulwe ngumzimba. I-Cannabidiol inokunciphisa ngokukhawuleza ukuba umzimba uphule njani i-stiripentol. Oku kunokunyusa amanqanaba e-stiripentol emzimbeni kunye nokunyusa iziphumo ebezingalindelekanga.
ITacrolimus (iPrograf)
I-Tacrolimus iyatshintshwa kwaye yaphulwe ngumzimba. I-Cannabidiol inokunciphisa ngokukhawuleza ukuba umzimba uphule njani i-tacrolimus. Oku kunokunyusa amanqanaba e-tacrolimus emzimbeni.
Itopiramate (iTompamax)
I-Topiramate iyatshintshwa kwaye yaphulwe ngumzimba. I-Cannabidiol inokunciphisa ngokukhawuleza ukuba umzimba uphule njani i-topiramate. Oku kunokunyusa amanqanaba e-topiramate emzimbeni ngesixa esincinci.
IValproate
I-Valproic acid inokubangela ukonzakala kwesibindi. Ukuthatha i-cannabidiol nge-valproic acid kunokunyusa amathuba okonzakala kwesibindi. I-Cannabidiol kunye / okanye i-valproic acid inokufuna ukumiswa, okanye idosi inokufuna ukunciphisa.
IWarfarin
I-Cannabidiol inokunyusa amanqanaba e-warfarin, anokunyusa umngcipheko wokopha. I-Cannabidiol kunye / okanye i-warfarin inokufuna ukumiswa, okanye idosi inokufuna ukunciphisa.
Zonisamide
I-Zonisamide iyatshintshwa kwaye yaphulwe ngumzimba. I-Cannabidiol inokunciphisa ngokukhawuleza ukuba umzimba uphule njani i-zonisamide. Oku kunokunyusa amanqanaba e-zonisamide emzimbeni ngesixa esincinci.
Iherbs kunye nezongezelelo ezineempawu zokuthomalalisa
I-Cannabidiol inokubangela ukulala okanye ukozela. Ukuyisebenzisa kunye namanye amayeza kunye nezongezo ezinefuthe elifanayo kunokubangela ukulala kakhulu. Ezinye zale mifuno kunye nezongezelelo zibandakanya i-calamus, i-poppy yaseCalifornia, i-catnip, i-hops, i-dogwood yase-Jamaican, i-kava, i-L-tryptophan, i-melatonin, i-sage, i-SAMe, i-wort yase-St.
Utywala (i-Ethanol)
Ukuthatha i-cannabidiol ngotywala kwandisa inani le-cannabidiol elifunxwa ngumzimba. Oku kunokunyusa iziphumo kunye neziphumo ebezingalindelekanga ze-cannabidiol.
Amafutha kunye nokutya okunamafutha
Ukuthatha i-cannabidiol ngesidlo esinamafutha amaninzi okanye ubuncinci inamafutha, inyusa inani le-cannabidiol elifunxwe ngumzimba. Oku kunokunyusa iziphumo kunye neziphumo ebezingalindelekanga ze-cannabidiol.
Ubisi
Ukuthatha i-cannabidiol ngobisi kwandisa inani le-cannabidiol elifunxwa ngumzimba. Oku kunokunyusa iziphumo kunye neziphumo ebezingalindelekanga ze-cannabidiol.
La machiza alandelayo afundwe kuphando lwezesayensi:

ABADALA

NGOMLOMO:
  • Isifo sokuwa: Imveliso ye-cannabidiol yemveliso (i-Epidiolex) isetyenzisiwe. Idosi yokuqala ecetyiswayo yeLennox-Gastaut syndrome kunye ne-Dravet syndrome yi-2.5 mg / kg kabini yonke imihla (5 mg / kg / ngosuku). Emva kweveki enye idosi inokunyuswa iye kwi-5 mg / kg kabini yonke imihla (10 mg / kg / ngosuku). Ukuba umntu akaphenduli kule dose, ubuninzi obucetyiswayo buyi-10 mg / kg kabini ngosuku (20 mg / kg / ngosuku). I-dose yokuqala ephakanyisiweyo ye-tuberous sclerosis complex is 2.5 mg / kg kabini ngosuku (5 mg / kg / ngosuku). Oku kungonyuswa rhoqo ngeveki xa kukho imfuneko, ukuya kuthi ga kwi-12.5 mg / kg kabini yonke imihla (25 mg / kg / ngosuku). Abukho ubungqina obuqinileyo benzululwazi bokuba iimveliso ze-cannabidiol ezingabhalwanga ziyanceda isifo sokuwa.
ABANTWANA

NGOMLOMO:
  • Isifo sokuwa: Imveliso ye-cannabidiol yemveliso (i-Epidiolex) isetyenzisiwe. Idosi yokuqala ecetyiswayo yeLennox-Gastaut syndrome kunye ne-Dravet syndrome yi-2.5 mg / kg kabini yonke imihla (5 mg / kg / ngosuku). Emva kweveki enye idosi inokunyuswa iye kwi-5 mg / kg kabini yonke imihla (10 mg / kg / ngosuku). Ukuba umntu akaphenduli kule dose, ubuninzi obucetyiswayo buyi-10 mg / kg kabini ngosuku (20 mg / kg / ngosuku). Umthamo ocetyiswayo wokuqala we-tuberous sclerosis complex ngu-2.5 mg / kg kabini ngemini (5 mg / kg / ngosuku). Oku kungonyuswa rhoqo ngeveki xa kukho imfuneko, ukuya kuthi ga kwi-12.5 mg / kg kabini yonke imihla (25 mg / kg / ngosuku). Abukho ubungqina obuqinileyo benzululwazi bokuba iimveliso ze-cannabidiol ezingabhalwanga ziyanceda isifo sokuwa.
2 - [(1R, 6R) -3-Methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl] -5-pentylbenzene-1,3-diol, CBD.

Ukuze ufunde okungakumbi malunga nokubhalwa kweli nqaku, nceda ubone Amayeza endalo aVimba weDatha indlela yokusebenza.


  1. U-Singh RK, uDillon B, uTatum DA, uVan Poppel KC, uBonthius DJ. Ukudibana kweziyobisi phakathi kweCannabidiol kunye neLithium. I-Neurol yomntwana evulekileyo. Ngo-2020; 7: 2329048X20947896. Jonga i-abstract.
  2. Izgelov D, Davidson E, Barasch D, Regev A, Domb AJ, Hoffman A. Uphando lwe-Pharmacokinetic yendlela yokwenziwa komlomo ye-cannabidiol kumavolontiya asempilweni. I-Eur J Pharm Biopharm. Ngo-2020; 154: 108-115. Jonga i-abstract.
  3. UGurley BJ, uMurphy TP, uGul W, u-Walker LA, u-ElSohly M. Umxholo xa kuthelekiswa namabango eelebhile e-Cannabidiol (CBD) -IziQulatho eziQokelelweyo eziFunyenwe kwiivenkile zorhwebo kwi-State of Mississippi. J Ukutya ukutya. Ngo-2020; 17: 599-607. Jonga i-abstract.
  4. UMcGuire P, uRobson P, uCubala WJ, et al. I-Cannabidiol (i-CBD) njengoNyango oluHlanganisiweyo kwiSchizophrenia: Isilingo esiLawulwayo esiLungelelanisiweyo esiManyeneyo. Am J Psychiatry. Ngo-2018; 175: 225-231. Jonga i-abstract.
  5. ICortopassi J. Warfarin uhlengahlengiso lwedosi efunekayo emva kokuqaliswa kwe-cannabidiol kunye nokubizwa. NdinguJ J Syst Pharm. Ngo-2020; 77: 1846-1851. Jonga i-abstract.
  6. IBloomfield MAP, iGreen SF, iHindocha C, et al. Iziphumo ze-cannabidiol ebukhali ekuhambeni kwegazi lobuchopho kunye nolwalamano lwayo nememori: Isifundo esibonisa ukubonwa kwemagneti. J Psychopharmacol. Ngo-2020; 34: 981-989. Jonga i-abstract.
  7. UWang GS, uBourne DWA, uKlawitter J, et al. Ukuchithwa kwe-Oral Cannabidiol-Rich Cannabis Extracts kuBantwana abane-Epilepsy. KwiKlinikhi Pharmacokinet. 2020. Jonga okungaqondakaliyo.
  8. UTaylor L, uCrockett J, uTayo B, uChecket D, uSommerville K. Ukurhoxa ngokukhawuleza kwe-cannabidiol (CBD): Ulingo olungenamsebenzi. Isifo sokuwa. 2020; 104 (Pt A): 106938. Jonga i-abstract.
  9. UMcNamara NA, uDang LT, uStrurza J, et al. I-Thrombocytopenia kwizigulana zabantwana kwi-cannabidiol efanayo kunye ne-valproic acid. Isifo sokuwa. 2020. Jonga okungaqondakaliyo.
  10. IRianprakaisang T, iGerona R, iHendrickson RG. Ioyile ye-cannabidiol yorhwebo engcoliswe yenziwa i-cannabinoid AB-FUBINACA enikwe isigulana sabantwana. KwiKlinikhi yetyhefu (Phila). NgoNovemba 2020; 58: 215-216. Jonga i-abstract.
  11. UMorrison G, Crockett J, Blakey G, Sommerville K. Isigaba 1, Ilebheli evulekileyo, iTyala lePhemacokinetic lokuphanda ukuNxibelelana kweziyobisi phakathi kweClobazam, iStiripentol, okanye iValproate kunye neCannabidiol kwizifundo ezinempilo. Iklinikhi ye-Pharmacol yeziyobisi. 2019; 8: 1009-1031. Jonga i-abstract.
  12. UMiller I, uScheffer IE, uGiking B, et al. Iziphumo eziDosiweyo zokuLungiswa komlomo we-Cannabidiol vs i-Placebo kwi-Convulsive Seizure Frequency kwi-Dravet Syndrome: Uvavanyo lweKlinikhi olungalindelekanga. IJAMA Neurol. Ngo-2020; 77: 613-621. Jonga i-abstract.
  13. ILattanzi S, iTrinka E, uStriano P, et al. Ukusebenza kwe-Cannabidiol kunye nenqanaba le-clobazam: Ukuphononongwa ngokuchanekileyo kunye nokuhlaziywa kwemeta. Isifo sokuwa. 2020; 61: 1090-1098. Jonga i-abstract.
  14. IHobbs JM, Vazquez AR, Remijan ND, et al. Uvavanyo lwe-pharmacokinetics kunye ne-anti-inflammatory enokubakho yamalungiselelo amabini e-cannabidiol yomlomo kubantu abadala abasempilweni. Phytother Res. Ngo-2020; 34: 1696-1703. Jonga i-abstract.
  15. Ebrahimi-Fakhari D, Agricola KD, Tudor C, Krueger D, Franz DN. I-Cannabidiol iphakamisa iithagethi zoMbane zeRapamycin Inhibitor Levels kwizigulana ezineTuberous Sclerosis Complex. UPediatr Neurol. 2020; 105: 59-61. Jonga i-abstract.
  16. de Carvalho Reis R, Almeida KJ, da Silva Lopes L, de Melo Mendes CM, Bor-Seng-Shu E.Ukusebenza kunye nomsitho ongathandekiyo we-cannabidiol kunye ne-cannabis yamayeza kunyango lwesifo sokuxhuzula: Ukuphononongwa ngokuchanekileyo kunye nohlalutyo lwe-meta. Ukuxhuzula Behav. 2020; 102: 106635. Jonga i-abstract.
  17. I-Darweesh RS, i-Khamis TN, i-El-Elimat T. Iziphumo ze-cannabidiol kwi-pharmacokinetics ye-carbamazepine kwiigundane. UNaunyn Schmiedebergs Arch Pharmacol. 2020. Jonga okungaqondakaliyo.
  18. ICrockett J, uCritchley D, uTayo B, uBerwaerts J, uMorrison G. Isigaba soku-1, esingahleliwe, isilingo se-pharmacokinetic seziphumo zokutya ezahlukeneyo, ubisi olupheleleyo, kunye notywala ekuvezeni i-cannabidiol kunye nokhuseleko kwizifundo ezisempilweni. Isifo sokuwa. Ngo-2020; 61: 267-277. Jonga i-abstract.
  19. UChesney E, u-Oliver D, uGreen A, et al. Iziphumo ezingalunganga ze-cannabidiol: uphononongo olucwangcisiweyo kunye nohlalutyo lweemeta zovavanyo lwezonyango olungenamsebenzi. Neuropsychopharmacology. 2020. Jonga okungaqondakaliyo.
  20. UBen-Menachem E, uGunning B, uArenas Cabrera CM, et al. Isigaba sesi-II sokuQiniseka ukuLinga ukuKhangela ukuNxibelelana kweFarmacokinetic iziyobisi kunye neStiripentol okanye iValproate xa zidityaniswe neCannabidiol kwizigulana ezinesifo sokuwa. Iziyobisi ze-CNS. Ngo-2020; 34: 661-672. Jonga i-abstract.
  21. IBass J, iLinz DR. Ityala lobutyhefu elivela kwi-Cannabidiol Gummy Ingestion. Cureus. 2020; 12: e7688. Jonga i-abstract.
  22. IHampson AJ, Grimaldi M, Axelrod J, Wink D.Cannabidiol kunye (-) Delta9-tetrahydrocannabinol zii-antioxidants ze-neuroprotective. Iprote Natl Acad Sci U S A. 1998; 95: 8268-73. Jonga i-abstract.
  23. IHacke ACM, uLima D, de Costa F, okqhubekayo. Ukuvavanya umsebenzi we-antioxidant we [delta] -tetrahydrocannabinol kunye ne-cannabidiol kwizicatshulwa zeCannabis sativa. Umhlalutyi. Ngo-2019; 144: 4952-4961. Jonga i-abstract.
  24. UMadden K, uTanco K, uBruera E.Ukusebenzisana ngokuBalulekileyo kweziyobisi neziyobisi phakathi kweMethadone kunye neCannabidiol. IPediatrics. 2020; e20193256. Jonga i-abstract.
  25. I-Hazekamp A. Ingxaki ngeoyile ye-CBD. I-Med Cannabis Cannabinoids. NgoJanuwari 2018; 1: 65-72.
  26. I-Xu DH, i-Cullen BD, i-Tang M, i-Fang Y. Ukusebenza kweoyile ye-Cannabidiol ye-Topical kwi-Sympomatic Relief ye-Peripheral Neuropathy ye-Lower Extremities. ICurr Pharm Biotechnol. 2019 Dec 1. Jonga into engabonakaliyo.
  27. de Faria SM, de Morais Fabrício D, Tumas V, okqhubekayo. Iziphumo zolawulo olunamandla lwe-cannabidiol kuxinzelelo kunye neenyikima ezibangelwa luVavanyo lokuThetha oluHlalisiweyo lukaRhulumente kwizigulana ezinesifo sikaParkinson. J Psychopharmacol. 2020 ngoJanuwari 7: 269881119895536. Jonga i-abstract.
  28. UNitecka-Buchta A, uNowak-Wachol A, uWachol K, et al. Isiphumo seMyorelaxant seTransdermal Isicelo seCannabidiol kwizigulana ezine-TMD: Isilingo esingahleliwe, esingaBoni kabini. J kwiiklinikhi. 2019 Novemba 6; 8. IPH: E1886. Jonga i-abstract.
  29. IMasataka N. Anxiolytic Iziphumo zokuphindaphinda unyango lweCannabidiol kulutsha olunengxaki yokuxhalaba ekuhlaleni. Ingqondo yangaphambili. Ngo-2019 uNov 8; 10: 2466. Jonga i-abstract.
  30. UAppiah-Kusi E, Petros N, Wilson R, et al. Iziphumo zonyango lwexesha elifutshane lwe-cannabidiol kwimpendulo yoxinzelelo lwentlalo kwizifundo ezisemngciphekweni omkhulu wokukhula kwengqondo. Ingqondo yengqondo (Berl). 2020 uJan 8. Jonga okungafakwanga.
  31. Hussain SA, Dlugos DJ, Cilio MR, Parikh N, Oh A, Sankar R. Synthetic amayeza ebanga i-cannabidiol kunyango lwe-spasms yeentsana ezichasayo: Isigaba se-2 sesifundo se-multicenter. Ukuxhuzula Behav. Ngo-2020 uJan; 102: 106826. Jonga i-abstract.
  32. UKlotz KA, Grob D, Hirsch M, Metternich B, Schulze-Bonhage A, Jacobs J.Ukusebenza kunye nokunyamezelana kwe-Synthetic Cannabidiol yoNyango lweSifo sokuXhuzula. Ngaphambili Neurol. Ngo-2019 uDisemba 10; 10: 1313. Jonga i-abstract.
  33. "I-GW Pharmaceuticals plc kunye ne-US Subsidiary Greenwich Biosciences, Inc. Yazisa ukuba i-EPIDIOLEX® (cannabidiol) Isisombululo somlomo sihlehlisiwe kwaye ayisasebenzi." Amachiza eGW, 6 Epreli 2020. http://ir.gwpharm.com/node/11356/pdf. Upapasho ndaba zekhampani.
  34. I-Wiemer-Kruel A, iStiller B, iBast T.Cannabidiol Inxibelelana ngokuBalulekileyo ne-Everolimus-Ingxelo yoMguli oneTuberous Sclerosis Complex. Neuropediatrics. 2019. Jonga okungaqondakaliyo.
  35. Uhlaziyo lwabathengi be-FDA: Into ekufuneka uyazi malunga nokusebenzisa i-Cannabis, kubandakanya i-CBD, xa ukhulelwe okanye uncancisa. U. S. Ukutya noLawulo lweziyobisi (FDA). Nge-Okthobha 2019. Iyafumaneka kwi: https://www.fda.gov/consumers/consumer-updates/what-you-should-now-about-using-cannabis-including-cbd-when-pregnant-or-breastfeeding.
  36. UTaylor L, Crockett J, Tayo B, Morrison G. Isigaba 1, Ilebheli evulekileyo, iQela eliDibeneyo, ukulingwa kwethamo elinye le-Pharmacokinetics kunye noKhuseleko lweCannabidiol (CBD) kwizifundo ezinobulali obunamandla bokuphazamiseka kweHepatic. J eKliniki kwi-Pharmacol. Ngo-2019; 59: 1110-1119. Jonga i-abstract.
  37. USzaflarski JP, uHernando K, uBebin EM, et al. Amanqanaba eplasma ephezulu ye-cannabidiol ayanyaniswa nempendulo yokubanjwa okungcono kulandela unyango lwe-cannabidiol. Isifo sokuwa. 2019; 95: 131-136. Jonga i-abstract.
  38. UPretzsch CM, uVoinescu B, uMendez MA, et al. Iziphumo ze-cannabidiol (i-CBD) kwimisebenzi yamaza asezantsi kunye nokunxibelelana okusebenzayo kwingqondo yabantu abadala kunye nangaphandle kwe-autism spectrum disorder (ASD). J Psychopharmacol. 2019: 269881119858306. Jonga i-abstract.
  39. I-Pretzsch CM, i-Freyberg J, i-Voinescu B, okqhubekayo. Iziphumo ze-cannabidiol kwinkqubo yokukhuthazeka kwengqondo kunye neenkqubo zokuthintela; Uvavanyo lwethamo elinye elilawulwa ngokungahleliwe ngexesha lokujonga imbonakalo yemagneti kubantu abadala abanengxaki yokuphazamiseka kwengqondo kwi-autism. Neuropsychopharmacology. Ngo-2019; 44: 1398-1405. Jonga i-abstract.
  40. U Patrician A, uVersic-Bratincevic M, uMijacika T, kunye no-al. Uvavanyo lwendlela entsha yokuhanjiswa kwe-Oral Cannabidiol kwizifundo ezisempilweni: Isifundo esingahleliwe, esingaboniyo, esilawulwa yiPlaceboin Pharmacokinetics. Ugqirha Ther. 2019. Jonga okungaqondakaliyo.
  41. UMartin RC, uGaston TE, uThompson M, et al. Ukusebenza kwengqondo emva kokusetyenziswa kwexesha elide kwe-cannabidiol kubantu abadala abanesifo sokuxhathisa esinganyangekiyo. Isifo sokuwa. Ngo-2019; 97: 105-110. Jonga i-abstract.
  42. I-Leino AD, i-Emoto C, i-Fukuda T, i-Privitera M, i-Vinks AA, i-Alloway RR. Ubungqina bokudibana kweziyobisi neziyobisi phakathi kwe-cannabidiol kunye ne-tacrolimus. NdinguJ. Ngo-2019; 19: 2944-2948. Jonga i-abstract.
  43. I-Laux LC, i-Bebin EM, i-Checketts D, okqhubekayo. Ukhuseleko lwexesha elide kunye nokusebenza kwe-cannabidiol ebantwaneni nakubantu abadala abanonyango olunganyangekiyo neLennox-Gastaut syndrome okanye iDravet syndrome: Iziphumo zolwandiso lokufikelela. Isifo sokuwa. Ngo-2019; 154: 13-20. Jonga i-abstract.
  44. UKnaub K, Sartorius T, Dharsono T, Wacker R, uWilhelm M, uSchön C. Inkqubo yokuNikezelwa kweziyobisi ezizimeleyo (i-SEDDS) esekwe kwiVESIsorb yokuQulunqa iTekhnoloji Ukuphucula ukufumaneka komlomo kweCannabidiol kwizifundo ezisempilweni. Iimolekyuli. 2019; 24. IPH: E2967. Jonga i-abstract.
  45. I-Klotz KA, Hirsch M, Heers M, Schulze-Bonhage A, Jacobs J. Iziphumo ze-cannabidiol kumanqanaba e-plasma ye-brivaracetam. Isifo sokuwa. 2019; 60: e74-e77. Jonga i-abstract.
  46. UHeussler H, uCohen J, uSilove N, et al. Isigaba se-1/2, uvavanyo lweelebhile ezivulekileyo zokhuseleko, ukunyamezeleka, kunye nokusebenza kwe-transdermal cannabidiol (ZYN002) kunyango lwe-X syndrome yabantwana. J Neurodev Ingxaki. Ngo-2019; 11: 16. Jonga i-abstract.
  47. Isofa DG, Cook H, Ortori C, Barrett D, Lund JN, O'Sullivan SE. I-Palmitoylethanolamide kunye ne-Cannabidiol Khusela ukuShukuma okuDala ukuDumba koLuntu kwi-Vitro nakwi-Vivo-A elawulwa ngokungekho mthethweni, elawulwa yi-Placebo. Ukudumba kwesisu Dis. 2019; 25: 1006-1018. Jonga i-abstract.
  48. Birnbaum AK, Karanam A, Marino SE, okqhubekayo. Iziphumo zokutya kwi-pharmacokinetics ye-cannabidiol yeepilisi zomlomo kwizigulana zabantu abadala abanokuxhuzula. Isifo sokuwa. 2019 Agasti; 60: 1586-1592. Jonga i-abstract.
  49. UA Arkell TR, uLintzeris N, uKevin RC, et al. Umxholo weCannabidiol (CBD) kwi-cannabis ephefumlelweyo awuthinteli ukungasebenzi kakuhle kwe-tetrahydrocannabinol (THC) yokuqhuba kunye nokuqonda. Ingqondo yengqondo (Berl). Ngo-2019; 236: 2713-2724. Jonga i-abstract.
  50. UAnderson LL, uAbhisalom NL, u-Abelev SV, et al. Coadministered cannabidiol kunye ne-clobazam: Ubungqina obuncinci bezinto zombini ezinxulumene ne-pharmacodynamic kunye ne-pharmacokinetic interaction. Isifo sokuwa. 2019. Jonga okungaqondakaliyo.
  51. Ulwazi ngemveliso yeMarinol. UAbbVie. EMantla eChicago, IL 60064. Agasti 2017.Ifumaneka kwi: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf.
  52. I-Epidiolex (cannabidiol) echaza ulwazi. IGreenwich Biosciences, Inc., iCarlsbad, i-CA, 2019. Iyafumaneka apha: https://www.epidiolex.com/sites/default/files/EPIDIOLEX_Full_Prescribing_Information.pdf (kufunyenwe nge-5/9/2019)
  53. Ingxelo evela kuMkomishinala we-FDA uScot Gottlieb, MD, ngokusayinwa koMthetho woPhuculo lwezoLimo kunye nokulawulwa kwe-arhente yeemveliso eziqukethe i-cannabis kunye ne-cannabis compounds. IWebhsayithi yoLawulo lwezoKutya noKutya. Ifumaneka apha: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-signing-agriculture-improvement-act-and-agencys. (Kufumaneka ngo-Meyi 7, 2019).
  54. UMthetho woPhuculo lwezoLimo, S. 10113, 115th Cong. okanye S. 12619, 115th Cong. .
  55. Ulawulo lokuNyanzeliswa kweziyobisi, iSebe lezoBulungisa. Iishedyuli zezinto ezilawulwayo: Ukubekwa kwiShedyuli V yeZiyobisi ezithile ezivunyiweyo ze-FDA eziqukethe iCannabidiol; Utshintsho oluhambelanayo neemfuno zemvume. Umyalelo wokugqibela. Ubhaliso lweFed. 2018 Sep 28; 83: 48950-3. Jonga i-abstract.
  56. ISchoedel KA, uSzeto I, uSetnik B, et al. Uvavanyo olunokubakho lokuxhatshazwa kwe-cannabidiol (i-CBD) kubasebenzisi bokuzonwabisa be-polydrug: Uvavanyo olungenamkhethe, oluyimfama, olulawulwayo. Isifo sokuwa. NgoNovemba 2018; 88: 162-171. ikhonkco: 10.1016 / j.yebeh.2018.07.027. Epub 2018 Okt 2. Jonga i-abstract.
  57. I-Devinsky O, Verducci C, Thiele EA, okqhubekayo. Ukusetyenziswa kwelebheli evulekileyo ye-CBD ehlanjululwe kakhulu (i-Epidiolex®) kwizigulana ezinesiphene se-CDKL5 kunye ne-Aicardi, iDup15q, kunye ne-Doose syndromes. Isifo sokuwa. 2018 Sep; 86: 131-137. Epub 2018 Jul 11. Jonga i-abstract.
  58. USzaflarski JP, uBebin EM, umsiki G, uDeWolfe J, et al. I-Cannabidiol iphucula ukuhamba rhoqo kunye nobukhali bokubanjwa kunye nokunciphisa izehlo ezichaseneyo kwilebula evulekileyo yokongeza isifundo. Isifo sokuwa. 2018 Oktobha; 87: 131-136. Epub 2018 Aug 9. Jonga i-abstract.
  59. IiLinares IM, iZuardi AW, iPereira LC, et al. I-Cannabidiol iveza umjikelo wokuphendula wethamo ophendulwa njenge-U kuvavanyo lokuthetha esidlangalaleni. UBraz J Psychiatry. 2019 Jan-Feb; 41: 9-14. Epub 2018 Okt 11. Jonga i-abstract.
  60. I-Poklis JL, Mulder HA, Uxolo MR. Ukuchongwa okungalindelekanga kwe-cannabimimetic, i-5F-ADB, kunye ne-dextromethorphan kwizibonelelo ezikhoyo zentengiso ze-cannabidiol e-liquids. I-Forensic Sci Int. 2019 uJan; 294: e25-e27. Epub 2018 Novemba 1. Jonga into engaqondakaliyo.
  61. Yenzakele YL, Spriggs S, Alishayev J, et al. I-Cannabidiol yokuNcitshiswa kwe-Cue-Induction Craving kunye nexhala kubantu abaNgena iziyobisi ngabantu abaneHeroin yoSetyenziso lokuPhazamiseka: Uvavanyo olulawulwa kabini oluLungelelaniswe ngePlacebo. NdinguJ J Psychiatry. 2019: appiajp201918101191. Jonga i-abstract.
  62. Thiele EA, Marsh ED, French JA, et al. I-Cannabidiol kwizigulana ezinokubanjwa ezinxulunyaniswa nesifo seLennox-Gastaut (GWPCARE4): ilingo elilawulwa ngokungacwangciswanga, elingaboniyo nelilawulayo le-3. ILancet. 2018 ngoMatshi 17; 391: 1085-1096. Jonga i-abstract.
  63. I-Devinsky O, Patel AD, Umnqamlezo JH, et al. Iziphumo zeCannabidiol ekubanjweni kweDrop kwiLennox-Gastaut Syndrome. N Engl J Med. 2018 ngoMeyi 17; 378: 1888-1897. Jonga i-abstract.
  64. IPavlovic R, uNenna G, uCalvi L, et al. Iimpawu zoMgangatho "wee-Cannabidiol Oils": Umxholo we-Cannabinoids, iTrintene Fingerprint kunye nozinzo lwe-Oxidation yoLungiselelo lwaseYurophu lokuThengisa. Iimolekyuli. 2018 ngoMeyi 20; 23. IPH: E1230. Jonga i-abstract.
  65. UJannasch F, uKröger J, uSchulze MB. Iipateni zokutya kunye nohlobo 2 lweSwekile: Uphononongo loncwadi olucwangcisiweyo kunye noVavanyo lweMeta yoPhononongo oluqinisekileyo. J Isondlo. Ngo-2017 uJuni; 147: 1174-1182. Jonga i-abstract.
  66. UNaftali T, uMechulam R, uMarii A, et al. Idosi ephantsi ye-cannabidiol ikhuselekile kodwa ayisebenzi kunyango lweSifo sikaCrohn, uvavanyo olulawulwa ngokungenamthetho. Ukumba iDisci. Ngo-2017 uJuni; 62: 1615-20. Jonga i-abstract.
  67. I-Kaplan EH, i-Offermann EA, iSievers JW, iComi AM. Unyango lweCannabidiol lokuthimba okungafunekiyo kwiStrurge-Weber Syndrome. UPediatr Neurol. Ngo-2017 uJuni; 71: 18-23.e2. Jonga i-abstract.
  68. Ewehurun ​​M, Shpilberg O, Herscovici C, et al. I-Cannabidiol yokuthintela isifo se-graft-versus-host-disease emva kokufakwa kweseli ye-hematopoietic cell: iziphumo zesifundo sesi-II. Ukutshintshwa kweBarrow Blood Marrow. Ngo-2015 Oktobha; 21: 1770-5. Jonga i-abstract.
  69. UGeffrey AL, uPollack SF, uBruno PL, uThiele EA. Ukusebenzisana kweziyobisi kunye neziyobisi phakathi kwe-clobazam kunye ne-cannabidiol kubantwana abanesifo sokuxhuzula. Isifo sokuwa. Ngo-2015 Agasti; 56: 1246-51. Jonga i-abstract.
  70. I-Devinsky O, Marsh E, Friedman D, et la. I-Cannabidiol kwizigulana ezinesifo sokuxhathisa esinganyangekiyo: isilingo esivulekileyo sokungenelela. ILancet Neurol. Ngo-2016 Mar; 15: 270-8. Jonga i-abstract.
  71. I-97021 Jadoon KA, iRatcliffe SH, iBarrett DA, okqhubekayo. Ukusebenza kunye nokukhuseleka kwe-cannabidiol kunye ne-tetrahydrocannabivarin kwi-glycemic kunye neepidid parameter kwizigulana ezinesifo seswekile sesi-2: isifundo esingahleliwe, esingaboniyo, esilawulwa yi-placebo, esilinganayo seqela lokuqhuba. Unonophelo lweSwekile. Ngo-2016 Oktobha; 39: 1777-86. Jonga i-abstract.
  72. IGofshteyn JS, uWilfong A, uDevinsky O, et al. I-Cannabidiol njengonyango olunokubakho kusulelo olunxulumene nesifo sokuwa (i-FIRES) kwizigaba ezibi kunye ezingapheliyo. J Umntwana Neurol. Ngo-2017 uJan; 32: 35-40. Jonga i-abstract.
  73. UHess EJ, uMoody KA, uGeffrey AL, et al. I-Cannabidiol njengonyango olutsha lwesifo sokuxhathisa amachiza kwisifo se-tuberous sclerosis. Isifo sokuwa. Ngo-2016 Oktobha; 57: 1617-24.
  74. IGaston TE, i-Bebin EM, i-Cutter GR, i-Liu Y, i-Szaflarski JP; Inkqubo ye-UAB CBD. Ukusebenzisana phakathi kwe-cannabidiol kunye neziyobisi eziqhelekileyo ezisetyenziswa kwi-antiepileptic. Isifo sokuwa. Ngo-2017 Sep; 58: 1586-92. Jonga i-abstract.
  75. I-Devinsky O, Umnqamlezo JH, uLaux L, et al. Uvavanyo lwe-cannabidiol yokubanjwa okunganyangekiyo ngamachiza kwi-Dravet Syndrome. N Engl J Med. Ngo-2017 ngoMeyi 25; 376: 2011-2020. Jonga i-abstract.
  76. UBonn-Miller MO, uLoflin MJE, uThomas BF, uMarcu JP, uHyke T, uVandrey R. Ukubhala ngokuchaneka kwezicatshulwa ze-cannabidiol ezithengiswe kwi-Intanethi. IJAMA 2017 Nov; 318: 1708-9. Jonga i-abstract.
  77. IMalfait AM, iGallily R, iSumariwalla PF, et al. I-non-psychoactive cannabis-constituent cannabidiol sisinyango somlomo esichasene ne-arthritic kwi-murine collagen-indened arthritis. Inkqubo yeNatl Acad Sci USA 2000; 97: 9561-6. Jonga i-abstract.
  78. IFomukong EA, uEvans AT, uEvans FJ. Umsebenzi we-analgesic kunye ne-anti-inflammatory of constituents of Cannabis sativa L.Ukuvuvukala 1988; 12: 361-71. Jonga i-abstract.
  79. UValvassori SS, uElias G, de Souza B, et al. Iziphumo ze-cannabidiol kwi-amphetamine-eyenze ukuba kuveliswe uxinzelelo lwe-oxidative kwimodeli yezilwanyana ye-mania. J I-Psychopharmacol 2011; 25: 274-80. Jonga i-abstract.
  80. U-Esposito G, uScuderi C, uSavani C, et al. I-Cannabidiol kwi-vivo blunts beta-amyloid induroinfigueation ngokucinezela i-IL-1beta kunye ne-iNOS expression. UBr J Pharmacol 2007; 151: 1272-9. Jonga i-abstract.
  81. U-Esposito G, uDe Filippis D, uMaiuri MC, et al. I-Cannabidiol inhibit inducible nitric oxide synthase expression expression kunye nemveliso ye-nitric oxide kwimveliso ye-beta-amyloid evuselelekileyo ye-PC12 neurons ngokusebenzisa i-p38 MAP kinase kunye ne-NF-kappaB yokuzibandakanya. I-Neurosci Lett 2006; 399 (1-2): 91-5. Jonga i-abstract.
  82. UIuvone T, uEsposito G, uDe Filippis D, et al. Ukuchaneka I-Cannabidiol: iyeza elitsha elithembisayo lokuphazamiseka kwemithambo-luvo? I-CNS Neurosci Ther 2009; 15: 65-75. Jonga i-abstract.
  83. I-Bisogno T, i-Di Marzo Y. Indima yenkqubo ye-endocannabinoid kwisifo se-Alzheimer's: iinyani kunye neengcinga. ICurr Pharm Des 2008; 14: 2299-3305. Jonga i-abstract.
  84. UZuardi AW. I-Cannabidiol: ukusuka kwi-cannabinoid engasebenziyo ukuya kwichiza elinendlela ebanzi yokusebenza. UMfu Bras Psiquiatr 2008; 30: 271-80. Jonga i-abstract.
  85. Izzo AA, uBorelli F, uCapasso R, et al. Isityalo esingasebenziyo se-psychotropic iinnabinoids: amathuba amatsha onyango kwi-herb yakudala. Iindlela ezihambelana neFarmacol Sci 2009; 30: 515-27. Jonga i-abstract.
  86. Booz GW. I-Cannabidiol njengesicwangciso esinyangayo sonyango sokunciphisa ifuthe lokudumba koxinzelelo lwe-oxidative. I-Radic Biol Med yasimahla ngo-2011; 51: 1054-61. Jonga i-abstract.
  87. Ukhetha iJT. Umsebenzi wokuhlaziya we-cannabis ngokunxulumene nomxholo we-delta'-trans-tetrahydrocannabinol kunye nomxholo we-cannabidiol. UBr J Pharmacol 1981; 72: 649-56. Jonga i-abstract.
  88. Imonti JM. Iziphumo zehypnotic ezifana ne-cannabidiol kumgangatho. I-Psychopharmacology (Berl) 1977; 55: 263-5. Jonga i-abstract.
  89. UKarller R, iTurkanis SA. Subacute unyango lwe-cannabinoid: Umsebenzi we-anticonvulsant kunye nokurhoxiswa kukonwaba kwiimpuku. UBr J Pharmacol 1980; 68: 479-84. Jonga i-abstract.
  90. UKarller R, uCely W, iTurkanis SA. Umsebenzi we-anticonvulsant we-cannabidiol kunye ne-cannabinol. Ubomi beSayensi ngo-1973; 13: 1527-31. Jonga i-abstract.
  91. I-Consroe PF, kunye neWokin AL. Ukudibana kwe-anticonvulsant ye-cannabidiol kunye ne-ethosuximide kwiigundane. UJ Pharm Pharmacol 1977; 29: 500-1. Jonga i-abstract.
  92. I-Consroe P, iWolkin A.Ukuthelekiswa kweziyobisi ze-Cannabidiol-antiepilpetic kunye nokunxibelelana ekubanjweni kweempuku. UJ Pharmacol Exp Ther 1977; 201: 26-32. Jonga i-abstract.
  93. ICarlini EA, iLeite JR, iTannhauser M, iBerardi AC. Ileta: I-Cannabidiol kunye ne-Cannabis sativa ikhupha iigundane kunye neempuku ngokuchasene nearhente yokuxhuzula. J Pharm Pharmacol 1973; 25: 664-5. Jonga i-abstract.
  94. UCryan JF, uMarkou A, uLucki I. Ukuvavanya ukusebenza kwe-antidepressant kwiintonga: uphuhliso lwamva nje kunye neemfuno zexesha elizayo. Imikhwa yeFarmacol Sci 2002; 23: 238-45. Jonga i-abstract.
  95. U-El-Alfy AT, u-Ivey K, uRobinson K, okqhubekayo. Isiphumo sokudakumba njengo-delta9-tetrahydrocannabinol kunye nezinye ii-cannabinoids ezizimele zodwa kwi-Cannabis sativa L. Pharmacol Biochem Behav 2010; 95: 434-42. Jonga i-abstract.
  96. I-Resstel LB, iTavares RF, iLisboa SF, et al. Ii-receptors ze-5-HT1A zibandakanyeka kulondolozo lwe-cannabidiol olubangelwa kukuziphatha kunye neempendulo zentliziyo kuxinzelelo olukhulu kwiigundane. Br J Pharmacol 2009; 156: 181-8. Jonga i-abstract.
  97. IGranjeiro EM, iGomes FV, ​​iGuimaraes FS, et al. Iziphumo zolawulo lwangaphakathi lwe-cannabidiol kwiimpendulo zentliziyo kunye nokuziphatha kuxinzelelo olukhulu lokuthintela. IPhemacol Biochem Behav 2011; 99: 743-8. Jonga i-abstract.
  98. UMurillo-Rodriguez E, uMillan-Aldaco D, uPalomero-Rivero M, et al. I-Cannabidiol, indawo yeCannabis sativa, imodareyitha ukulala kwiigundane. IINKCUKACHA ZENKQUBO 2006; 580: 4337-45. Jonga i-abstract.
  99. UDe Filippis D, uEsposito G, uCirillo C, et al. I-Cannabidiol inciphisa ukuvuvukala kwamathumbu ngokulawulwa kwe-axis ye-neuroimmune. I-PLoS enye ngo-2011; 6: e28159. Jonga i-abstract.
  100. UBhattacharyya S, uFusar-Poli P, uBorgwardt S, et al. Ukuguqulwa kwemisebenzi ye-mediotemporal kunye ne-ventrostriatal ebantwini ngu-Delta9-tetrahydrocannabinol: isiseko se-neural seziphumo ze-Cannabis sativa ekufundeni nakwisifo sengqondo. IArch Gen Psychiatry 2009; 66: 442-51. Jonga i-abstract.
  101. UDalton WS, uMartz R, uLemberger L, et al. Impembelelo ye-cannabidiol kwi-delta-9-tetrahydrocannabinol. KwiKlinikhi ye-Pharmacol Ther 1976; 19: 300-9. Jonga i-abstract.
  102. IGuimaraes VM, iZuardi AW, iDel Bel EA, iGuimaraes FS. I-Cannabidiol yonyusa intetho ye-Fos kwi-nucleus accumbens kodwa hayi kwi-dorsal striatum. Ubomi beSayensi 2004; 75: 633-8. Jonga i-abstract.
  103. IMoreira FA, iGuimaraes FS. I-Cannabidiol inqanda i-hyperlocomotion ebangelwa ngamachiza e-psychomimetic kwiigundane. I-Eur J Pharmacol 2005; 512 (2-3): 199-205. Jonga i-abstract.
  104. Ixesha elide LE, uChesworth R, uHuang XF, et al. Ukuthelekiswa kokuziphatha kwe-Delta9-tetrahydrocannabinol ebukhali nengapheliyo kwi-C57BL / 6JArc iimpuku. I-Int J Neuropsychopharmacol 2010; 13: 861-76. Jonga i-abstract.
  105. UZuardi AW, uRodriguez JA, uCunha JM. Iziphumo ze-cannabidiol kwiimodeli zezilwanyana zokuxelwa kwangaphambili komsebenzi we-antipsychotic. I-Psychopharmacology (Berl) 1991; 104: 260-4. Jonga i-abstract.
  106. IMalone DT, uJongejan D, uTaylor DA. I-Cannabidiol ibuyisela umva ukuncipha kunxibelelwano lwasentlalweni oluveliswe yidosi esezantsi ye-Delta-tetrahydrocannabinol kwiigundane. IPhemacol Biochem Behav 2009; 93: 91-6. Jonga i-abstract.
  107. ISchubart CD, iSommer IE, uFusar-Poli P, et al. I-Cannabidiol njengonyango olunokubakho kwisifo sengqondo. I-Eur Neuropsychopharmacol 2014; 24: 51-64. Jonga i-abstract.
  108. ICampos AC, iMoreira FA, kunye neGomes FV, ​​et al. Iindlela ezininzi ezibandakanyeka kunyango olukhulu lwento enokubakho ye-cannabidiol kukuphazamiseka kwengqondo. IPhilos Trans R Soc Lond B Biol Sci 2012; 367: 3364-78. Jonga i-abstract.
  109. UFusar-Poli P, uAllen P, uBhattacharyya S, et al. Ukumodareyitha kokunxibelelana okusebenzayo ngexesha lokuqhutywa kweemvakalelo nguDelta 9-tetrahydrocannabinol kunye ne-cannabidiol. I-Int J Neuropsychopharmacol 2010; 13: 421-32. Jonga i-abstract.
  110. ICasarotto PC, iGomes FV, ​​iResstel LB, iGuimaraes FS. Impembelelo ye-Cannabidiol yokuthintela isimilo sokungcwaba imarble: ukubandakanyeka kwee-receptors ze-CB1. I-Behav Pharmacol 2010; 21: 353-8. Jonga i-abstract.
  111. Uribe-Marino A, uFrancisco A, uCastiblanco-Urbina MA, et al. Iziphumo ezichasene ne-anti-aversive ze-cannabidiol kwiindlela zokuziphatha ezenziwa ngaphakathi zoloyiko ezikhutshwe yimodeli yokuziphatha yohlaselo olusekwe kwixhoba ngokuchasene nenyoka yasendle Epicrate cenchria crassus yokujongana neparadigm. I-Neuropsychopharmacology 2012; 37: 412-21. Jonga i-abstract.
  112. ICampos AC, iGuimaraes FS. Ukwenza kusebenze ii-5HT1A receptors kulamla uxinzelelo lwe-cannabidiol kwimodeli ye-PTSD. I-Behav Pharmacol 2009; 20: S54.
  113. I-Resstel LB, iJoca SR, iMoreira FA, et al. Iziphumo ze-cannabidiol kunye ne-diazepam kwindlela yokuziphatha kunye neempendulo zentliziyo ezibangelwa luloyiko kwimeko yeempuku. I-Behav yeBrain Res 2006; 172: 294-8. Jonga i-abstract.
  114. IMoreira FA, iAguiar DC, iGuimaraes FS. Iziphumo ezinjenge-Anxiolytic ze-cannabidiol kuvavanyo lwempixano ye-Vogel. Inkqubo Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1466-71. Jonga i-abstract.
  115. U-Onaivi ES, uGreen MR, uMartin BR. Ukubonakaliswa kwe-Pharmacological ye-cannabinoids kwindawo ephezulu yokudibanisa. J Pharmacol Exp Ther 1990; 253: 1002-9. Jonga i-abstract.
  116. IGuimaraes FS, Chairetti TM, iGraeff FG, iZuardi AW. Isiphumo sokuxhalaba kwe-cannabidiol kwi-plus-maze ephakamileyo. I-Psychopharmacology (Berl) 1990; 100: 558-9. Jonga i-abstract.
  117. UMagen I, uAvraham Y, uAckerman Z, et al. I-Cannabidiol yonyusa ukuqonda kunye nokuphazamiseka kwemoto kwiimpuku ezine-bile duct ligation. J IHepatol 2009; 51: 528-34. Jonga i-abstract.
  118. URajesh M, uMukhopadhyay P, Batkai S, et al. I-Cannabidiol ifumana ukungasebenzi kakuhle kwentliziyo, uxinzelelo lwe-oxidative, i-fibrosis, kunye nokuvuvukala kunye nokufa kweseli ekubonakaliseni indlela kwisifo seswekile. NdinguColl Cardiol 2010; 56: 2115-25. Jonga i-abstract.
  119. U-El-Remessy AB, uKhalifa Y, u-Ola S, et al. I-Cannabidiol ikhusela i-retinal neurons ngokugcina umsebenzi we-glutamine synthetase kwisifo seswekile. I-Mol Vis 2010; 16: 1487-95. Jonga i-abstract.
  120. U-El-Remessy AB, uAl-Shabrawey M, uKhalifa Y, et al. I-Neuroprotective kunye ne-retina yegalelo lokugcina isithintelo kwi-cannabidiol kwisifo seswekile sokulinga. NdinguJ Pathol 2006; 168: 235-44. Jonga i-abstract.
  121. URajesh M, uMukhopadhyay P, Batkai S, et al. I-Cannabidiol ifumanisa i-glucose ephezulu-induces endothelial cell reaction reaction and barriers. NdinguJ Physiol Intliziyo yeSekethe yePhysol 2007; 293: H610-H619. Jonga i-abstract.
  122. I-CC yeToth, iJedrzejewski NM, i-Ellis CL, iFrey WH. Ukumodareyithwa kwe-Cannabinoid-Mediated ye-neuropathic yentlungu kunye nokuqokelelwa kwe-microglial kwimodeli yohlobo lwe-murine 1 yeswekile yesifo se-neuropathic. Ubunzima beMol 2010; 6: 16. Jonga i-abstract.
  123. UAviello G, uRomano B, uBorrelli F, et al. Isiphumo seChemopreventive ye-non-psychotropic phytocannabinoid cannabidiol kumhlaza womhlaza wolingo. UJ Mol Med (Berl) 2012; 90: 925-34. Jonga i-abstract.
  124. ULee CY, Wey SP, uLiao MH, et al. Uphononongo lokuthelekisa i-apoptosis ye-cannabidiol-indased in murine thymocytes kunye ne-EL-4 thymoma cell. I-Immunopharmacol 2008; 8: 732-40. Jonga i-abstract.
  125. UMassi P, uValenti M, uVaccani A, et al. I-5-Lipoxygenase kunye ne-anandamide hydrolase (FAAH) yokulamla kwimisebenzi ye-antitumor ye-cannabidiol, i-non-psychoactive cannabinoid. J Neurochem 2008; 104: 1091-100. Jonga i-abstract.
  126. UValenti M, uMassi P, uBolognini D, et al. I-Cannabidiol, i-non-psychoactive i-cannabinoid compound inqanda ukufuduka kweseli ye-glioma kunye ne-invasiveness. I-34 ye-National Congress yoMbutho wase-Italiya weFarmacology ngo-2009.
  127. UTorres S, uLorente M, uRodriguez-Fornes F, et al. Unyango oluhlangeneyo lonyango lwe-cannabinoids kunye ne-temozolomide ngokuchasene ne-glioma. Umhlaza weCancer Ther 2011; 10: 90-103. Jonga i-abstract.
  128. UJacobsson SO, uRongard E, uStridh M, et al. Iziphumo ezixhomekeke kwiserum ze-tamoxifen kunye ne-cannabinoids kwi-C6 glioma yeseli esebenzayo. Biochem Pharmacol 2000; 60: 1807-13. Jonga i-abstract.
  129. I-Shrivastava A, iNkulumbuso ye-Kuzontkoski, i-Groopman JE, i-Prasad A.I-Cannabidiol inceda ukubulawa kweseli okucwangcisiweyo kwiiseli zomhlaza wamabele ngokulungelelanisa intetho yomnqamlezo phakathi kwe-apoptosis kunye ne-autophagy. Umhlaza weCancer Ther 2011; 10: 1161-72. Jonga i-abstract.
  130. UMcAllister SD, uMurase R, uChristian RT, et al. Iindlela zokulamla iziphumo ze-cannabidiol ekunciphiseni ukwanda kwesifo somhlaza webele, ukuhlasela kunye ne-metastasis. Unyango lomhlaza wamabele kunyango luka-2011; 129: 37-47. Jonga i-abstract.
  131. UMcAllister SD, uChristian RT, uMphathiswa waseHorowitz, et al. I-Cannabidiol njenge-inhibitor yenoveli ye-Id-1 expression expression kwiiseli zomhlaza wamabele. Umhlaza weCancer Ther 2007; 6: 2921-7. Jonga i-abstract.
  132. ILigresti A, iMoriello AS, iStarowicz K, et al. Umsebenzi we-Antitumor wezityalo ze-cannabinoids kugxininiso kwiziphumo ze-cannabidiol kwi-carcinoma yebele yomntu. UJ Pharmacol Exp Ther 2006; 318: 1375-87. Jonga i-abstract.
  133. UMassi P, uSolinas M, uCinquina V, uParolaro D.Cannabidiol njengechiza elinokubangela umdlavuza. UBr J Clin Pharmacol 2013; 75: 303-12. Jonga i-abstract.
  134. ISchubart CD, iSommer IE, van Gastel WA, et al. I-Cannabis enomxholo ophezulu we-cannabidiol unxulunyaniswa namava ambalwa engqondo. ISchizophr Res 2011; 130 (1-3): 216-21. Jonga i-abstract.
  135. U-Englund A, uMorrison PD, u-Nottage J, et al. I-Cannabidiol inqanda i-THC-ephakanyisiweyo yeempawu zeparanoid kunye ne-hippocampal-exhomekeke kwimemori. J I-Psychopharmacol 2013; 27: 19-27. Jonga i-abstract.
  136. I-Devinsky O, uCilio MR, Umnqamlezo H, et al. I-Cannabidiol: i-pharmacology kunye nendima enokubakho kunyango kwisifo sokuwa kunye nezinye iingxaki ze-neuropsychiatric. Isifo sokuwa 2014; 55: 791-802. Jonga i-abstract.
  137. I-Serpell MG, i-Notcutt W, i-Collin C.Usetyenziso lwexesha elide lwe-Sativex: isilingo esivulekileyo seelebhile kwizigulana ezinesplinity ngenxa ye-multiple sclerosis. J Neurol 2013; 260: 285-95. Jonga i-abstract.
  138. I-Notcutt W, iLangford R, uDavies P, okqhubekayo. Iqela elilawulwa yi-placebo, iqela elilinganayo, ukufundwa kokurhoxa kwizifundo ezineempawu zokuxinana ngenxa ye-multiple sclerosis efumana i-Sativex yexesha elide (nabiximols). IMult Scler 2012; 18: 219-28. Jonga i-abstract.
  139. UBrady CM, iDasGupta R, uDalton C, et al. Uphononongo oluvulekileyo lweelebheli kwizicatshulwa ze-cannabis ezenzelwe ukungasebenzi kakuhle kwesinyi kwi-multiple sclerosis. IMult Scler 2004; 10: 425-33. Jonga i-abstract.
  140. IKavia RB, uDe Ridder D, uConstantinescu CS, et al. Ulingo olulawulwa ngokungekho mthethweni lweSativex ukunyanga ukungasebenzi ngakumbi kwe-detrusor kwi-multiple sclerosis. IMult Scler 2010; 16: 1349-59. Jonga i-abstract.
  141. Wade DT, PM Makela PM, House H, et al. Ukusetyenziswa kwexesha elide kunyango olusekwe kwi-cannabis kwi-spasticity kunye nezinye iimpawu kwi-multiple sclerosis. IMult Scler 2006; 12: 639-45. Jonga i-abstract.
  142. INovotna A, Mares J, Ratcliffe S, et al. I-randomized, i-blind-blind, i-placebo elawulwa yi-placebo, iqela elihambelanayo, ukucwangciswa koyilo lwe-nabiximols * (Sativex), njengokongezwa kwonyango, kwizifundo ezinokuphambuka okubangelwa yi-multiple sclerosis. I-Eur J Neurol 2011; 18: 1122-31. Jonga i-abstract.
  143. Ushwankathelo. Indawo yeWebhu ye-GW.Ifumaneka kwi: http://www.gwpharm.com/about-us-overview.aspx. Kufumaneka: Meyi 31, 2015.
  144. I-Cannabidiol Ngoku ibonakalisa kwizongezelelo zokutya. Iwebhsayithi yamayeza endalo. https://naturalmedicines.therapeuticresearch.com/news/news-items/2015/march/cannabidiol-now-showing-up-in-dietary-supplements.aspx. (Kufumaneka ngo-Meyi 31, 2015).
  145. IZuardi AW, iCosme RA, iGraeff FG, iGuimaraes FS. Iziphumo ze-ipsapirone kunye ne-cannabidiol kuxinzelelo lovavanyo lomntu. J Psychopharmacol 1993; 7 (1 iSuppl): 82-8. Jonga i-abstract.
  146. I-EG ejikelezayo, i-Fentiman AF Jr, iFoltz RL. Imetabolites ezigcinwe ixesha elide ze-delta9- kunye ne-delta8-tetrahydrocannabinols ezichongiweyo njengeenoveli ezinamafutha acid Indawo ye-Comm Comm Chem Pathol Pharmacol 1976; 14: 13-28. Jonga i-abstract.
  147. USamara E, uBialer M, uMechoulam R. Pharmacokinetics we-cannabidiol ezinjeni. Ukulahlwa kweMetab yeziyobisi 1988; 16: 469-72. Jonga i-abstract.
  148. I-Consroe P, iSandyk R, iSnider SR. Vula uvavanyo lweelebheli lwe-cannabidiol kukuphazamiseka kwentshukumo ye-dystonic. I-Int J Neurosci 1986; 30: 277-82 (PubMed) (Umnqamlezo) Jonga i-abstract.
  149. UCrippa JA, uDerenusson GN, uFerrari TB, et al. Isiseko se-Neural seziphumo zexhala le-cannabidiol (i-CBD) kwimeko yoxinzelelo lwentlalo ngokubanzi: ingxelo yokuqala. J I-Psychopharmacol 2011; 25: 121-30. Jonga i-abstract.
  150. U-Bornheim LM, u-Everhart ET, uLi J, uCorreia MA. Ukuchongwa kwe-cytochrome P450 ye-cannabidiol-Mediated. Biochem Pharmacol 1993; 45: 1323-31. Jonga i-abstract.
  151. UHarvey DJ. Ukufunxa, ukuhanjiswa, kunye ne-biotransformation ye-cannabinoids. Intsangu kunye noNyango. Ngo-1999; 91-103.
  152. Yamaori S, Ebisawa J, Okushima Y, et al. Uthintelo olunamandla lwe-cytochrome yabantu i-P450 3A isoforms yi-cannabidiol: indima yamaqela e-phenolic hydroxyl kwindawo ye-resorcinol. Ubomi beSayensi ngo-2011; 88 (15-16): 730-6. Jonga i-abstract.
  153. I-Yamaori S, i-Okamoto Y, i-Yamamoto I, i-Watanabe K. Cannabidiol, eyona phytocannabinoid enkulu, njenge-inhibitor enamandla ye-atypical ye-CYP2D6. Ukulahlwa kweMetab yeziyobisi ngo-2011; 39: 2049-56. Jonga i-abstract.
  154. I-Yamaori S, Maeda C, Yamamoto I, Watanabe K. Umahluko kuthintelo lwe-cytochrome yabantu i-P450 2A6 kunye ne-2B6 yi-phytocannabinoids eziphambili. I-Forensic Toxicol 2011; 29: 117-24.
  155. I-Yamaori S, Kushihara M, Yamamoto I, Watanabe K. Ukubonakaliswa kweepytocannabinoids eziphambili, i-cannabidiol kunye ne-cannabinol, njenge-isoform-ekhethiweyo inhibitors ezinamandla ze-CYP1 enzymes. Biochem Pharmacol 2010; 79: 1691-8. Jonga i-abstract.
  156. UZuardi AW, uCrippa JA, uHallak JE, et al. I-Cannabidiol kunyango lwe-psychosis kwisifo sika-Parkinson. J I-Psychopharmacol 2009; 23: 979-83. Jonga i-abstract.
  157. UMorgan CJ, uDas RK, uJoye A, et al. I-Cannabidiol inciphisa ukusetyenziswa kwecuba kubantu abatshayayo: iziphumo zokuqala. Iziyobisi Behav 2013; 38: 2433-6. Jonga i-abstract.
  158. IPertwee RG. I-CB1 eyahlukeneyo kunye ne-CB2 receptor pharmacology yezityalo ezintathu ze-cannabinoids: i-delta9-tetrahydrocannabinol, i-cannabidiol kunye ne-delat9-tetrahydrocannabivarin. UBr J Pharmacol 2008; 153: 199-215. Jonga i-abstract.
  159. ILeweke FM, uKranaster L, uPahlisch F, et al. Ukusebenza kwe-cannabidiol kunyango lwe-schizophrenia-indlela yokuguqulela. ISchizophr Bull 2011; 37 (iSuppl 1): 313.
  160. ILeweke FM, uPiomelli D, uPahlisch F, et al. I-Cannabidiol inyusa ukubonakaliswa kwe-anandamide kunye nokunciphisa iimpawu zengqondo ye-schizophrenia. Guqula i-Psychiatry 2012; 2: e94. Jonga i-abstract.
  161. UCarroll CB, uBain PG, uTeare L, et al. I-Cannabis ye-dyskinesia kwisifo sika-Parkinson: isifundo se-crossover esingaboniyo. Neurology 2004; 63: 1245-50. Jonga i-abstract.
  162. IBergamaschi MM, iQueiroz RH, iChagas MH, et al. I-Cannabidiol inciphisa uxinzelelo olubangelwa kukuthetha esidlangalaleni kunyango lwe-naïve yezigulana zentlalo. I-Neuropsychopharmacology 2011; 36: 1219-26. Jonga i-abstract.
  163. UZuardi AW, uCrippa JA, uHallak JE, et al. I-Cannabidiol, indawo ye-Cannabis sativa, njengechiza lokulwa nonyango. IBraz J Med Biol Res 2006; 39: 421-9. Jonga i-abstract.
  164. UYadav V, uBever C Jr, uBowen J, et al. Isishwankathelo sesikhokelo esisekwe kubungqina: iyeza elongezayo kunye nelinye kwi-multiple sclerosis: ingxelo yekomitana yokuphuhlisa isikhokelo seAmerican Academy of Neurology. Neurology. Ngo-2014; 82: 1083-92. Jonga i-abstract.
  165. U-Trembly B, uSherman M. Uphononongo lweklinikhi olungaboniyo kabini njenge-anticonvulsant yesibini. Ingqungquthela yamazwe ngamazwe yentsangu '90 yeCannabis kunye neCannabinoids 1990; 2: 5.
  166. Srivastava, M. D., Srivastava, B. I., kunye noBrouhard, B. Delta9 tetrahydrocannabinol kunye ne-cannabidiol eguqula ukuveliswa kwe-cytokine ngamaseli omzimba omntu. I-Immunopharmacology 1998; 40: 179-185. Jonga i-abstract.
  167. UCunha, JM, Carlini, EA, Pereira, AE, Ramos, OL, Pimentel, C., Gagliardi, R., Sanvito, WL, Lander, N., kunye noMechoulam, R. Ulawulo olungapheliyo lwe-cannabidiol kumavolontiya asempilweni nakwizigulana ezinesifo sokuwa. . Ikhemesti 1980; 21: 175-185. Jonga i-abstract.
  168. ICarlini EA, iCunha JM. Iziphumo zehypnotic kunye ne-antiepileptic ye-cannabidiol. J Clin Pharmacol 1981; 21 (8-9 Suppl): 417S-27S. Jonga i-abstract.
  169. UZuardi, A. W., Shirakawa, I., Finkelfarb, E., kunye noKarniol, I. G. Isenzo se-cannabidiol kuxinzelelo nakwezinye iziphumo eziveliswa yi-delta 9-THC kwizifundo eziqhelekileyo. I-Psychopharmacology (Berl) 1982; 76: 245-250 (PubMed) (Umnqamlezo) Jonga i-abstract.
  170. Ames, F. R. kunye neCridland, S.Impembelelo yeAnticonvulsant ye-cannabidiol. Umva we-S.Afr. 1-4-1986; 69:14. Jonga i-abstract.
  171. U-Ohlsson, A., Lindgren, J. E., Andersson, S., Agurell, S., Gillespie, H., noHollister, L. E. Idosi enye ye-kinetics ye-deuterium enelebheli ye-cannabidiol emntwini emva kokutshaya kunye nolawulo lokungena. I-Biomed.Environ Ubuninzi beSpectrom. Ngo-1986; 13: 77-83. Jonga i-abstract.
  172. UWade, D.T, uCollin, uC., UStott, uC, noDuncombe, uP.Uhlalutyo lweemeta malunga nokusebenza kunye nokhuseleko lweSativex (nabiximols), kubuninzi babantu abane-sclerosis. Isandi seScler. Ngo-2010; 16: 707-714. Jonga i-abstract.
  173. UCollin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Novakova, mna ., Zapletalova, O., Pikova, J., kunye no-Ambler, Z. Uphononongo oluyimfama, olulawulwa ngokungekho mthethweni, olulawulwa yi-placebo, olufanayo lweqela le-Sativex, kwizifundo ezineempawu zokuphamba ngenxa yesifo sokuqina kwemithambo. I-Neurol. Ngo-2010; 32: 451-459. Jonga i-abstract.
  174. Crippa, J. A., Zuardi, A. W., Martin-Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., kunye noFusar-Poli, P. I-Cannabis kunye noxinzelelo: uphononongo olunzulu lobungqina. Hum. IPsychopharmacol. Ngo-2009; 24: 515-523. Jonga i-abstract.
  175. Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., noSchram, K. Ulawulo lwezonyango olulawulwayo lwe-cannabidiol kwisifo sikaHuntington. I-Pharmacol Biochem, iBhahav. Ngo-1991; 40: 701-708. Jonga i-abstract.
  176. UHarvey, D. J., Samara, E., kunye noMechoulam, R. Thelekisa imetabolism ye-cannabidiol kwinja, kumqolo nakumntu. I-Pharmacol Biochem, iBhahav. Ngo-1991; 40: 523-532. Jonga i-abstract.
  177. UCollin, C., Davies, P., Mutiboko, K., noRatcliffe, S. Uvavanyo olulawulwa ngokungahleliwe lwamayeza asekwe kwi-cannabis kwi-spasticity ebangelwa sisifo se-sclerosis. I-Eur. J. Neurol. Ngo-2007; 14: 290-296. Jonga i-abstract.
  178. Massi, P., Vaccani, A., Bianchessi, S., Costa, B., Macchi, P., kunye noParolaro, D. I-non-psychoactive cannabidiol ibangela ukwenziwa kwe-caspase kunye noxinzelelo lwe-oxidative kwiiseli ze-glioma zabantu. Iseli Mol. Ubomi beSayensi. Ngo-2006; 63: 2057-2066. Jonga i-abstract.
  179. Weiss, L., Zeira, M., Reich, S., Har-Noy, M., Mechoulam, R., Slavin, S., kunye noGallily, R.I-Cannabidiol yehlisa imeko yesifo seswekile kwiimpuku zeswekile ezingatyebanga. Ukuzimela ngokuzenzekelayo ngo-2006; 39: 143-151. Jonga i-abstract.
  180. I-Watzl, B., Scuderi, P., kunye noWatson, R. R. Izinto zentsangu zivuselela ukujikeleza kwegazi kwiseli ye-interferon-gamma kunye nokucinezela i-interleukin-1 alpha in vitro. Int J Immunopharmacol. Ngo-1991; 13: 1091-1097. Jonga i-abstract.
  181. I-Consroe, P., Kennedy, K., kunye ne-Schram, K. Uvavanyo lwe-plasma cannabidiol nge-capillary gas chromatography / ion trap mass spectroscopy elandela idosi ephezulu ephindaphindwayo yolawulo lomlomo ebantwini. I-Pharmacol Biochem, iBhahav. Ngo-1991; 40: 517-522. Jonga i-abstract.
  182. UBarnes, M. P. Sativex: ukusebenza kweeklinikhi kunye nokunyamezelana kunyango lweempawu zesifo sokuqina kwemithambo kunye neentlungu zentliziyo. Ingcali.Opin.Pharmacother. Ngo-2006; 7: 607-615. Jonga i-abstract.
  183. Wade, D.T, Makela, P., Robson, P., House, H., kunye noBateman, C. Ngaba izicatshulwa zamayeza ezisekwe kwi-cannabis zinempembelelo ngokubanzi okanye ezithile kwiimpawu kwi-multiple sclerosis? Uphononongo olulawulwa kabini, olungenamkhethe, olulawulwa yi-placebo kwizigulana ezili-160. Isandi seScler. Ngo-2004; 10: 434-441. Jonga i-abstract.
  184. Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., kunye neIzzo, isiphumo se-AA Neuroprotective ye-cannabidiol, icandelo elingasebenziyo kwi-Cannabis sativa, kwi-beta-amyloid Ityhefu kwiiseli ze-PC12. J Neurochem. Ngo-2004; 89: 134-141. Jonga i-abstract.
  185. Massi, P., Vaccani, A., Ceruti, S., Colombo, A., Abbracchio, M. P., kunye noParolaro, D. Iziphumo zeAntitumor ze-cannabidiol, i-cannabinoid engasebenziyo, kwimigca yeseli ye-glioma. J Pharmacol ukuThengisa. Ngo-2004; 308: 838-845. Jonga i-abstract.
  186. Crippa, JA, Zuardi, AW, Garrido, GE, Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, PM, Hallak, JE, McGuire, PK, kunye noFoho, Busatto G. Iziphumo ye-cannabidiol (i-CBD) kukuhamba kwegazi lobuchopho kwingingqi. Neuropsychopharmacology 2004; 29: 417-426. Jonga i-abstract.
  187. Wade, D.T, Robson, P., House, H., Makela, P., kunye no-Aram, J. Uphononongo lokuqala olulawulwayo lokufumanisa ukuba ngaba zonke izicatshulwa ze-cannabis zingaziphucula na iimpawu ze-neurogenic. KwiKlinikhi. Ngo-2003; 17: 21-29. Jonga i-abstract.
  188. ICovington TR, okqhubekayo. Incwadi yesandla yeziyobisi ezingabhaliswanga. Ngomhla we-11. IWashington, DC: Umbutho wamayeza waseMelika, ngo-1996.
Ukuhlaziywa okokugqibela-12/18/2020

Sikucebisa

Yintoni ebangela ukuGxothwa okuBrown emva kwexesha lam?
Zempilo

Yintoni ebangela ukuGxothwa okuBrown emva kwexesha lam?

Kanye xa ucinga ukuba ixe ha lakho liphelile, uyo ula kwaye ufumane ukukhut hwa okumdaka. Kuyakhathaza- kwaye ku enokwenzeka ukuba kuyothu a- njengoko kunokuba njalo, ukukhut hwa okumdaka emva kwexe h...
Uvavanyo lwe-Urine Umchamo (Umchamo woVavanyo lweeyure ezingama-24)
Zempilo

Uvavanyo lwe-Urine Umchamo (Umchamo woVavanyo lweeyure ezingama-24)

U hwankatheloI-Creatinine yimveli o yenkunkuma yemichiza eveli wa yimetaboli m yemi ipha. Xa izint o zakho zi ebenza nge iqhelo, zihluza i-creatinine kunye nezinye iimveli o zenkunkuma ngaphandle kwe...